Peptide therapy is a marketing phrase, not a type of FDA approval. Clinics use it for treatments built on peptides. Legally, a clinic can prescribe FDA-approved peptide medicines and, in limited cases, compounded drugs from licensed pharmacies. Research-grade peptides are laboratory reagents and have no place in that care. This guide explains what is allowed in 2026, how to check a clinic or telehealth service, and what to ask. Sources were checked on November 17, 2026.
Quick answer: Peptide therapy is legal when it means a licensed prescriber, an FDA-approved medicine or a lawfully compounded drug, and a licensed pharmacy. A "research use only" label does not make it legal to sell a product for people to use. Before you pay a clinic, check the prescriber, the pharmacy and whether the product is FDA-approved.
This article summarizes public regulatory records. It is not legal or medical advice, and it does not endorse any clinic or treatment.
What does "peptide therapy" mean?
The phrase has no legal definition. FDA says it "approves new human drugs and biological products" but "does not 'approve' health care providers" (FDA, 2026). So no clinic is FDA-approved, and the question is always about the product.
Under that label, a clinic might offer an approved medicine such as tesamorelin or a GLP-1 drug. It might also offer a compounded drug, or a product with no legal path at all. Our list of FDA-approved peptide medicines shows which peptides are real approved drugs.
What can a peptide clinic legally provide?
Table 1 compares what a clinic may offer and who stands behind each product.
What a peptide clinic may offer (checked November 17, 2026)
| Product | FDA-approved? | Main oversight | Key limit |
|---|---|---|---|
| Approved peptide medicine | Yes | FDA review of the product | Prescription; state-licensed pharmacy |
| 503A compounded drug | No | State boards of pharmacy | Identified patient, valid prescription, eligible ingredient |
| 503B compounded drug | No | FDA registration and inspection | Bulks list or shortage list rules |
| Research-grade peptide | No | No review for human use | Laboratory research use only |
Approved medicines. A prescriber may choose an approved drug for its labeled use. FDA says providers "generally may prescribe the drug for an unapproved use" when they judge it medically appropriate. FDA adds that it has not confirmed such uses are safe and effective (FDA, 2018).
Compounded drugs. FDA says compounded drugs should be used only when an approved drug cannot meet a patient's medical needs. It does not verify their safety, effectiveness or quality before they are sold (FDA, 2025). Our guide to 503A and 503B compounding explains the two systems.
Research-grade peptides. These are laboratory reagents for laboratory research use only, not for human or veterinary use. FDA has warned companies that sold research-labeled GLP-1 products directly to consumers for human use (FDA, 2026). See what research use only means.
Which peptides can be compounded in 2026?
A 503A pharmacy may use a bulk ingredient only if it passes one of three tests. It must have a USP or NF monograph, be in an approved drug, or be on the 503A bulks list. While FDA builds that list, it sorts nominated substances into interim categories. Category 2 means FDA "has identified significant safety risks relating to the use of these substances in compounding" (FDA, 2026). The 503A bulks list itself names six substances, and none is a peptide (21 CFR 216.23). Here is where common peptides stand.
- Category 2 today: kisspeptin-10 for 503A; GHRP-2, GHRP-6 and ipamorelin acetate for 503B (FDA, 2026).
- Previously category 2: BPC-157, TB-500, MOTS-c, KPV, CJC-1295, Semax, Selank and others, after nominators withdrew them. Withdrawal did not add them to the 503A bulks list.
- Retatrutide and cagrilintide: FDA says they "cannot be used in compounding under federal law" (FDA, 2026).
- Semaglutide and tirzepatide: FDA says they "do not currently appear on the 503B bulks list or on FDA's drug shortage list" (FDA, 2026). See is semaglutide legal.
On October 30, 2026, HHS published a draft policy. HHS "does not intend to take enforcement action" against certain 503A compounders using peptides in its Appendix A (HHS, 2026). The Federal Register text does not name those peptides. The policy covers 503A only, "is not binding on HHS or the public," and may be revisited if a safety signal arises. Compounded drugs remain unapproved. Our page on the HHS 503A peptide policy covers it in full.
How do you check a peptide clinic or telehealth service?
FDA lists warning signs for telehealth and online sellers. Be careful if a company does any of the following.
- does not require a screening and prescription by a licensed doctor;
- has no licensed doctor available for questions after you receive the medicine;
- claims a compounded drug is the same as an FDA-approved drug;
- offers prices that seem too good to be true;
- sends medicine with label errors or a pharmacy name you cannot verify.
In March 2026, FDA warned 30 telehealth companies over compounded GLP-1 marketing, including claims implying sameness with approved products (FDA, 2026).
Then check the people and places behind the product. Ask for the prescriber's full name and look up the license with your state's licensing board. Find the dispensing pharmacy in FDA's state-licensed pharmacy lookup. FDA says that if a pharmacy is not listed, you should not use it. A 503B facility should appear on FDA's list of registered outsourcing facilities.
What questions should you ask a peptide clinic?
- Is this product FDA-approved, and is it approved for my condition?
- If it is compounded, which pharmacy makes it? Is that a 503A pharmacy or a 503B outsourcing facility, and is it licensed in my state?
- Why do I need this treatment, and are there alternatives? AHRQ suggests both questions (AHRQ, 2020).
- What side effects should I watch for, and will it interact with my other medicines?
- Who reviews my health history, and who do I contact if something goes wrong?
- Will you report side effects to FDA's MedWatch program?
If a clinic cannot answer these clearly, treat that as a warning sign. For the wider picture, see how to get peptides legally and peptides and the FDA in 2026.
What should you do if something goes wrong?
- Get care. Call 911 in an emergency, or contact a licensed clinician.
- Poison Help: 1-800-222-1222, or poison.org.
- Report it to FDA through MedWatch, or call 1-888-INFO-FDA (1-888-463-6332) and press 2.
- Tell the source. FDA also suggests contacting the compounder or telehealth platform that supplied the drug.
Frequently asked questions about peptide therapy
What is peptide therapy, and is it legal?
It is a marketing term for treatments built on peptides, not an FDA category. It is legal when a licensed prescriber uses an FDA-approved medicine or a lawfully compounded drug from a licensed pharmacy.
How do I know if a peptide clinic or telehealth prescription is legitimate?
A legitimate service screens you, has a licensed prescriber and names a licensed pharmacy. Check the pharmacy in FDA's state-licensed pharmacy lookup, and be wary of claims that a compounded drug equals an approved one.
Is peptide therapy FDA-approved?
FDA approves specific drugs, not therapies or clinics. Some peptide medicines are FDA-approved, while compounded drugs and research-grade peptides are not.
Can a 503A pharmacy compound BPC-157?
BPC-157 is not on the 503A bulks list as of November 17, 2026, and FDA lists it as previously in its safety-risk category. FDA has posted no final decision after its July 2026 advisory committee review.
Does the HHS peptide policy approve any peptides?
No. The October 2026 notice is a draft, non-binding enforcement policy for certain 503A compounders, and it states that compounded drugs are not FDA-approved.
Can a clinic use research-grade peptides?
Research-grade peptides are laboratory reagents for laboratory research use only, not for human or veterinary use. They are not FDA-approved medicines or compounded drugs from a licensed pharmacy.
What to know now
- No approval for clinics: FDA approves drugs, not providers or "therapies."
- Legal products: FDA-approved medicines and lawfully compounded drugs, on prescription.
- Compounded: not FDA-approved; limited by the 503A and 503B rules.
- HHS draft policy: October 30, 2026; 503A only; not binding; approves nothing.
- Check first: prescriber license, pharmacy license, and whether the product is approved.
What we're watching
A final HHS peptide compounding policy and its Appendix A. Any FDA decision on the peptides discussed in July 2026. New FDA action against telehealth companies.